Last update 28 Feb 2025
SuZhou Teligene Ltd.

SuZhou Teligene Ltd.

Holding Company | Subsidiary Company|
2011|
Jiangsu Sheng, China
|
www.teligenebio.cn

Overview

Tags

Neoplasms
Respiratory Diseases
Digestive System Disorders
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms11
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug11
Top 5 TargetCount
EGFR(Epidermal growth factor receptor erbB1)2
BTK x EGFR T790M1
ALK x NTRK x ROS11
ALK(Anaplastic lymphoma kinase)1
HER2(Receptor tyrosine-protein kinase erbB-2)1

Related

11
Drugs associated with SuZhou Teligene Ltd.
Sutetinib Maleate
Target
EGFR L861Q mutation x EGFR S768I mutation x EGFR-G719X
Mechanism
EGFR L861Q mutation antagonists [+2]
Active Org.
SZYY Group Pharmaceutical Ltd.SZYY Group Pharmaceutical Ltd. [+2]
Originator Org.
SZYY Group Pharmaceutical Ltd.SZYY Group Pharmaceutical Ltd.
Active Indication
metastatic non-small cell lung cancer [+3]
Inactive Indication
Advanced Malignant Solid Neoplasm
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Kenaitinib
Target
BTK x EGFR T790M
Mechanism
BTK inhibitors [+1]
Active Org.
Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd.Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd.
Originator Org.
Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd.Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd.
Active Indication
Advanced Lung Non-Small Cell Carcinoma [+8]
Inactive Indication
Brain metastases [+1]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
TL-938
Target
HER2
Mechanism
HER2 antagonists
Active Org.
SuZhou Teligene Ltd.SuZhou Teligene Ltd.
Originator Org.
SuZhou Teligene Ltd.SuZhou Teligene Ltd.
Active Indication
Metastatic Colorectal Carcinoma [+2]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
22
Clinical Trials associated with SuZhou Teligene Ltd.
NCT06589830
/ Not yet recruitingPhase 2
A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer
NCT06010329
/ RecruitingPhase 2
A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
CTR20230812
/ CompletedPhase 1
[14C]马来酸苏特替尼在中国男性健康受试者中的物质平衡及代谢研究
[Translation] Study on the material balance and metabolism of [14C] sutetinib maleate in healthy Chinese male subjects
100 Clinical Results associated with SuZhou Teligene Ltd.
Login to view more data
0 Patents (Medical) associated with SuZhou Teligene Ltd.
Login to view more data
100 Deals associated with SuZhou Teligene Ltd.
Login to view more data
100 Translational Medicine associated with SuZhou Teligene Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
3
Phase 1
Phase 2
5
6
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free